Results 1 to 10 of about 5,225 (154)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis) [PDF]

International Journal of Molecular Sciences, 2021
Transthyretin (TTR) amyloidogenesis involves the formation, aggregation, and deposition of amyloid fibrils from tetrameric TTR in different organs and tissues. While the result of amyloidoses is the accumulation of amyloid fibrils resulting in end-organ damage, the nature, and sequence of the molecular causes leading to amyloidosis may differ between ...
Alejandra González-Duarte, Alfredo Ulloa-Aguirre   +1 more
exaly   +5 more sources

ATTR Variant Amyloidosis in Patients with Dysphagia

Surgeries, 2023
Amyloidosis is a rare disease characterized by the accumulation of misfolded extracellular proteins in various organs. Over 30 precursor proteins have been identified that can form amyloid deposits in different parts of the body.
Christina Ng, Gerald Berry, Edward Damrose   +2 more
exaly   +4 more sources

Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review [PDF]

BMC Musculoskeletal Disorders, 2023
Background Hereditary and wild-type transthyretin-mediated (ATTRv and ATTRwt) amyloidoses result from the misfolding of transthyretin and aggregation of amyloid plaques in multiple organ systems.
Emre Aldinc, Courtney Campbell, Finn Gustafsson, Abigail Beveridge, Richard Macey, Laura Marr, Catherine Summers, Dafang Zhang   +7 more
doaj   +2 more sources

Diagnosis and Treatment of AL and ATTR Amyloidosis. [PDF]

J Adv Pract Oncol, 2021
At JADPRO Live Virtual 2020, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®, differentiated between AL and ATTR amyloidosis, discussed key considerations in selecting therapy, and identified ways that advanced practitioners can manage the supportive care needs of this patient population.
Faiman B, Richards T.
europepmc   +4 more sources

Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review [PDF]

Orphanet Journal of Rare Diseases
Introduction Significant advances in the treatment of transthyretin (ATTR) amyloidosis has led to an evolving understanding of the epidemiology of this condition. This systematic literature review (SLR) aims to synthesize current evidence on epidemiology
Diego Delgado, Firas Dabbous, Nitin Shivappa, Faizan Mazhar, Eric Wittbrodt, Divya Shridharmurthy, Krister Järbrink   +6 more
doaj   +2 more sources

Disease burden of ATTR amyloidosis based on the SF-36® health survey [PDF]

Cardio-Oncology
Transthyretin (ATTR) amyloidosis is a progressive systemic disease associated with substantial morbidity and mortality. Although health-related quality of life (HRQoL) assessments are increasingly incorporated into clinical trials, data in ATTR ...
Vaishali Sanchorawala, Alexandra Greatsinger, Andrew Staron, John L. Berk, Lisa M. Mendelson, Tracy Joshi, Natasha J. Burke, Nadia Tabatabaeepour, Jess Smith, James Signorovitch   +9 more
doaj   +2 more sources

Glavonoid, a possible supplement for prevention of ATTR amyloidosis. [PDF]

Heliyon, 2021
Transthyretin (TTR) is an amyloidogenic protein associated with hereditary and nonhereditary transthyretin amyloidoses (ATTR). Dissociation of the tetramer of TTR to the monomer induces TTR misfolding, which leads to amyloid fibril formation and triggers the onset of ATTR amyloidosis.
Matsushita H, Isoguchi A, Okada M, Masuda T, Misumi Y, Tsutsui C, Yamaguchi N, Ichiki Y, Sawashita J, Ueda M, Mizuguchi M, Ando Y.   +11 more
europepmc   +5 more sources

Structure-Based Probe Reveals the Presence of Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients [PDF]

JACC: Basic to Translational Science
Summary: Amyloidogenic transthyretin (ATTR) amyloidosis is a relentlessly progressive disease caused by the misfolding and systemic accumulation of amyloidogenic transthyretin into amyloid fibrils.
Rose Pedretti, BS, Lanie Wang, BS, Anna Yakubovska, MS, Qiongfang S. Zhang, BS, Binh Nguyen, PhD, Justin L. Grodin, MD, Ahmad Masri, MD, Lorena Saelices, PhD   +7 more
doaj   +2 more sources

Transthyretin Kinetic Stabilizers for ATTR Amyloidosis. [PDF]

Cardiol Ther
Kelly JW.
europepmc   +3 more sources

Conventional heart failure therapy in cardiac ATTR amyloidosis [PDF]

European Heart Journal, 2023
Adam Ioannou, Alun Hughes, Nick Freemantle   +2 more
exaly   +2 more sources